Related Experiment Video

Updated: Nov 2, 2025

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.8K

Angiogenesis Inhibitors in Small Cell Lung Cancer

Agnese Montanino1, Anna Manzo1, Guido Carillio2

  • 1Thoracic Department, Istituto Nazionale Tumori, IRCCS "Fondazione G.Pascale", Naples, Italy.

Frontiers in Oncology
|June 14, 2021
PubMed

Insights

Angiogenesis inhibitors targeting vascular endothelial growth factor (VEGF) show limited efficacy in small cell lung cancer (SCLC). Anlotinib is approved as third-line therapy in China, but further research is needed.

Area of Science:

  • Oncology
  • Cancer Research
  • Translational Medicine

Background:

  • Angiogenesis inhibition is a validated cancer treatment strategy.
  • Vascular endothelial growth factor (VEGF) drives tumor growth and is overexpressed in small cell lung cancer (SCLC).

Purpose of the Study:

  • To review the efficacy of angiogenesis inhibitors in small cell lung cancer (SCLC).
  • To identify challenges and future directions for anti-angiogenic therapy in SCLC.

Main Methods:

  • Systematic review of clinical trials evaluating angiogenesis inhibitors in SCLC.
  • Analysis of treatment outcomes, including progression-free survival (PFS) and overall survival (OS).

Main Results:

  • Bevacizumab showed improved PFS but not OS in first-line ES-SCLC.
  • Most other angiogenesis inhibitors failed to demonstrate significant benefit in first- or second-line SCLC.
  • Anlotinib improved OS and PFS as third-line therapy in Chinese SCLC patients and is approved in China.

Conclusions:

  • Angiogenesis inhibitors have shown limited success in SCLC, with notable exceptions like anlotinib in specific settings.
  • Future research should explore combinations of angiogenesis inhibitors with immunotherapy and chemotherapy, alongside biomarker identification.
Keywords:
angiogenesisanlotinibbevacizumabsmall cell lung cancervascular endothelial growth factor

More Related Videos

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

9.9K
Author Spotlight: Investigating Angiogenesis and Vessel Permeability Through a Modified Matrix Gel Plug Assay09:03

Author Spotlight: Investigating Angiogenesis and Vessel Permeability Through a Modified Matrix Gel Plug Assay

Published on: June 30, 2023

1.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.9K
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
6.2K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.1K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
791